These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29206243)

  • 21. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
    J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.
    Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F
    Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
    Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
    Chen B; Hu N
    Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets.
    González-Mariscal I; Montoro RA; Doyle ME; Liu QR; Rouse M; O'Connell JF; Santa-Cruz Calvo S; Krzysik-Walker SM; Ghosh S; Carlson OD; Lehrmann E; Zhang Y; Becker KG; Chia CW; Ghosh P; Egan JM
    Diabetologia; 2018 Jun; 61(6):1470-1483. PubMed ID: 29497784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model.
    Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27928909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corrigendum.
    Sun XH; Yu HZ; Yang MM; Yang YM; Dang ZM
    J Cachexia Sarcopenia Muscle; 2015 Jun; 6(2):192. PubMed ID: 26140254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
    Strack AM; Nicolich S; Faidley T; Achanfuo-Yeboah J; Cunningham PK; Hora D; Thompson D; Hickey G; Johnson-Levonas AO; Fong TM; Heymsfield SB
    Metabolism; 2012 Apr; 61(4):546-53. PubMed ID: 22001334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.
    Cinar R; Gochuico BR; Iyer MR; Jourdan T; Yokoyama T; Park JK; Coffey NJ; Pri-Chen H; Szanda G; Liu Z; Mackie K; Gahl WA; Kunos G
    JCI Insight; 2017 Apr; 2(8):. PubMed ID: 28422760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Profiling of CB1 Neutral Antagonists.
    Seltzman HH; Maitra R; Bortoff K; Henson J; Reggio PH; Wesley D; Tam J
    Methods Enzymol; 2017; 593():199-215. PubMed ID: 28750803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
    Seltzman HH; Shiner C; Hirt EE; Gilliam AF; Thomas BF; Maitra R; Snyder R; Black SL; Patel PR; Mulpuri Y; Spigelman I
    J Med Chem; 2016 Aug; 59(16):7525-43. PubMed ID: 27482723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.
    Cinar R; Iyer MR; Liu Z; Cao Z; Jourdan T; Erdelyi K; Godlewski G; Szanda G; Liu J; Park JK; Mukhopadhyay B; Rosenberg AZ; Liow JS; Lorenz RG; Pacher P; Innis RB; Kunos G
    JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corrigendum: β2-Adrenergic Receptor-Mediated HIF-1α Upregulation Mediates Blood Brain Barrier Damage in Acute Cerebral Ischemia.
    Sun Y; Chen X; Zhang X; Shen X; Wang M; Wang X; Liu WC; Liu CF; Liu J; Liu W; Jin X
    Front Mol Neurosci; 2017; 10():392. PubMed ID: 29204110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
    Boon MR; Kooijman S; van Dam AD; Pelgrom LR; Berbée JF; Visseren CA; van Aggele RC; van den Hoek AM; Sips HC; Lombès M; Havekes LM; Tamsma JT; Guigas B; Meijer OC; Jukema JW; Rensen PC
    FASEB J; 2014 Dec; 28(12):5361-75. PubMed ID: 25154875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.